Recent Updates in the Treatment of CML

Dana-Farber Cancer Institute
Avatar

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone for BCR-ABL1+ ALL and Blast Phase CML in Adults"

By Dana-Farber Cancer Institute FEATURING Marlise R. Luskin
By Dana-Farber Cancer Institute FEATURING Marlise R. Luskin
207 views
December 20, 2023
Comments 0
Login to view comments. Click here to Login
06:26

Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …

Akriti Jain

89 views
07:55

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

635 views
17:47

Treating CML Patients With TKI Resistance vs. TKI Intolerance

The University of Alabama at Birmingham School of Medicine

O. Jamy

297 views
18:55

iCMLf Conversations: CML Clinical Highlights of EHA 2023

International CML Foundation

A. Hochhaus

155 views
17:30

SOHO 2023: Rational TKI Choice in CML

SOHO 2023 Eleventh Annual Meeting

M. Deininger

309 views
16:25

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross

430 views
06:15

Unmet Needs in CML: Patient & Physician Perspectives From the CML SU…

Jorge Cortés

82 views
04:16

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

948 views
08:32

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Treatmen…

Insights from 2023 ASH Annual Meeting

D. Yeung

125 views